Appointment

Proteome Sciences PLC
4 June 2001

                                PRESS RELEASE

4 June 2001

               PROTEOME SCIENCES APPOINTS DR GUNTER SCHMIDT AS

                            NON-EXECUTIVE DIRECTOR


Proteome Sciences plc (Proteome Sciences), the AIM listed proteomics and
modification of gene expression company, is pleased to announce that Dr Gunter
Schmidt will be joining the Board of the Company as a non-executive Director
later this month.


Dr Gunter Schmidt was founder and executive director of Brax Group Limited
(Brax), a company specializing in high throughput genomic/proteomic
technology. He sold the business to Aventis Research and Technology GmbH
(Aventis) in November 2000 and since then has acted as a corporate consultant
to Aventis.


Before founding Brax, Dr Schmidt was an associate director of biochemistry at
Merck Sharp and Dohme Inc at Rahway, New Jersey, USA and prior to that, Head
of Mammalian Genetics at Glaxo Group Research Limited in the UK.


Dr Schmidt completed his degree and PhD at Reading University, UK before
moving to the Institute of Cancer Research, with Professor Bruce Ponder in
London, UK.


This appointment follows the recent announcement of Dr Anthony Walker's
appointment as a non-executive Director and together with the Scientific
Advisory Board adds to the considerable bank of scientific knowledge and
commercial experience available to Proteome Sciences.


Christopher Pearce, Chief Executive of Proteome Sciences, commenting on this
appointment said:


        'Dr Schmidt's knowledge and expertise gained from his positions both
        from big pharma and the emerging biotechnology industry will add
        considerable value and strength to commercialise the technology
        platforms that we have at Proteome Sciences, in particular in
        proteomics. In addition to his role as a non-executive director, he
        will be acting in a strategic business development capacity as a
        consultant to the Company.'


                                     ENDS


For further information please contact:

Proteome Sciences plc   Tel: [phone]

Christopher Pearce, Chief Executive


Public Relations

Ikon Associates

Adrian Shaw   Tel: [phone]   Mobile: [phone]

E-mail:[e-mail]